This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Puzianowska-Kuznicka, M. Articles by Nauman, J. Search for Related Content PubMed PubMed Citation Articles by Puzianowska-Kuznicka, M. Articles by Nauman, J.

Functionally Impaired TR Mutants Are Present in Thyroid Papillary Cancer

Department of Endocrinology, Medical Research Center, Polish Academy of Sciences (M.P.-K., A.K., A.M., J.N.), and Department of Biochemistry, Medical Center of Postgraduate Education (M.P.-K.), 02-097 Warsaw, Poland; and Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health (S.-Y.C.), Bethesda, Maryland 20892

Address all correspondence and requests for reprints to: Dr. Monika Puzianowska-Kuznicka, Department of Endocrinology, Medical Research Center, 1a Banacha Street, 02-097 Warsaw, Poland. E-mail: . monika{at}amwaw.edu.pl

Abstract

TRs are transcription factors that regulate cell proliferation, differentiation, and apoptosis. They are cellular homologs of the transcriptionally inactive viral oncogene v-erbA. We tested the hypothesis that the functions of TRs could be impaired in cancer tissues as a result of aberrant expression and/or somatic mutations. As a model system, we selected human thyroid papillary cancer, in which the most common abnormalities, RET/papillary thyroid cancer rearrangements (fusion of RET kinase domain to the activating domains of other genes), were found in 40–45% of cases. We found that the mean expression levels of TRß mRNA and TR mRNA were significantly lower, whereas the protein levels of TRß1 and TR1 were higher in cancer tissues than in healthy thyroid. Sequencing of TRß1 and TR1 cDNAs, cloned from 16 papillary cancers, revealed that mutations affected receptor amino acid sequences in 93.75% and 62.5% of cases, respectively. In contrast, no mutations were found in healthy thyroid controls, and only 11.11% and 22.22% of thyroid adenomas had such TRß1 or TR1 mutations, respectively. The majority of the mutated TRs lost their trans-activation function and exhibited dominant negative activity. These findings suggest a possible role for mutated thyroid hormone receptors in the tumorigenesis of human papillary thyroid carcinoma.

This article has been cited by other articles:

				M. D. Rosen and M. L. Privalsky Thyroid Hormone Receptor Mutations Found in Renal Clear Cell Carcinomas Alter Corepressor Release and Reveal Helix 12 as Key Determinant of Corepressor Specificity Mol. Endocrinol., August 1, 2009; 23(8): 1183 - 1192. [Abstract] [Full Text] [PDF]

				B. Joseph, M. Ji, D. Liu, P. Hou, and M. Xing Lack of Mutations in the Thyroid Hormone Receptor (TR) {alpha} and Genes but Frequent Hypermethylation of the TR Gene in Differentiated Thyroid Tumors J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4766 - 4770. [Abstract] [Full Text] [PDF]

				A. S. Rocha, R. Marques, I. Bento, R. Soares, J. Magalhaes, I. V. de Castro, and P. Soares Thyroid hormone receptor {beta} mutations in the 'hot-spot region' are rare events in thyroid carcinomas J. Endocrinol., January 1, 2007; 192(1): 83 - 86. [Abstract] [Full Text] [PDF]

				S. J. Marx and W. F. Simonds Hereditary Hormone Excess: Genes, Molecular Pathways, and Syndromes Endocr. Rev., August 1, 2005; 26(5): 615 - 661. [Abstract] [Full Text] [PDF]

				Y. Takiyama, N. Miyokawa, A. Sugawara, S. Kato, K. Ito, K. Sato, K. Oikawa, H. Kobayashi, S. Kimura, and M. Tateno Decreased Expression of Retinoid X Receptor Isoforms in Human Thyroid Carcinomas J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5851 - 5861. [Abstract] [Full Text] [PDF]

				J. Kohrle Guard Your Master: Thyroid Hormone Receptors Protect Their Gland of Origin from Thyroid Cancer Endocrinology, October 1, 2004; 145(10): 4427 - 4429. [Full Text] [PDF]

				Y. Kato, H. Ying, M. C. Willingham, and S.-Y. Cheng A Tumor Suppressor Role for Thyroid Hormone {beta} Receptor in a Mouse Model of Thyroid Carcinogenesis Endocrinology, October 1, 2004; 145(10): 4430 - 4438. [Abstract] [Full Text] [PDF]

				H. Ying, H. Suzuki, L. Zhao, M. C. Willingham, P. Meltzer, and S.-Y. Cheng Mutant Thyroid Hormone Receptor {beta} Represses the Expression and Transcriptional Activity of Peroxisome Proliferator-activated Receptor {gamma} during Thyroid Carcinogenesis Cancer Res., September 1, 2003; 63(17): 5274 - 5280. [Abstract] [Full Text] [PDF]

				H. Ying, H. Suzuki, H. Furumoto, R. Walker, P. Meltzer, M. C. Willingham, and S.-Y. Cheng Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma Carcinogenesis, September 1, 2003; 24(9): 1467 - 1479. [Abstract] [Full Text] [PDF]

				T. Takano, A. Miyauchi, H. Yoshida, Y. Nakata, K. Kuma, and N. Amino Expression of TR{beta}1 mRNAs with Functionally Impaired Mutations Is Rare in Thyroid Papillary Carcinoma J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3447 - 3449. [Abstract] [Full Text] [PDF]

				A. Vivaldi, F. Pacini, F. Martini, L. Iaccheri, F. Pezzetti, R. Elisei, A. Pinchera, P. Faviana, F. Basolo, and M. Tognon Simian Virus 40-Like Sequences from Early and Late Regions in Human Thyroid Tumors of Different Histotypes J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 892 - 899. [Abstract] [Full Text] [PDF]

				M. Nygard, G. M. Wahlstrom, M. V. Gustafsson, Y. M. Tokumoto, and M. Bondesson Hormone-Dependent Repression of the E2F-1 Gene by Thyroid Hormone Receptors Mol. Endocrinol., January 1, 2003; 17(1): 79 - 92. [Abstract] [Full Text] [PDF]